Tiziana Scarna

Tiziana Scarna

Auto-generated profile, based on publicly available information

Tiziana Scarna

Gavi, The Vaccine Alliance, Global Health Campus, Chemin du Pommier 40, 1218 Le Grand-Saconnex, Geneva, Switzerland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Vaccine
Verified
Journal Article
Open access
MMMercy Mvundura
Mercy Mvundura
CFCollrane Frivold
Collrane Frivold
AOAnna Janik Osborne
Anna Janik Osborne
PSPriyanka Soni
Priyanka Soni
JRJoanie Robertson
Joanie Robertson
DKDebra Kristensen
Debra Kristensen
As part of the Vaccine Innovation Prioritisation Strategy (VIPS), three immunization-stakeholder consultations were conducted between September 2018 and February 2020 to ensure that countries' needs drove the prioritization of vaccine product innovations. All consultations targeted respondents with immunization program experience. They included: (1) an online survey to identify immunization implementation barriers and desired vaccine attributes in three use settings, (2) an online survey to identify and evaluate the most important immunization challenges for ten exemplar vaccines, and (3) in-depth interviews to better understand the perceived programmatic benefits and challenges that could be addressed by nine innovations and to rank the innovations that could best address current challenges. The first consultation included responses from 442 participants in 61 countries, representing 89% of the 496 respondents who correctly completed at least one section of the online survey. For facility-based settings, missed opportunities for vaccination due to reluctance to open multidose vaccine vials was the barrier most frequently selected by respondents. In community-based (outreach) and campaign settings, limited access to immunization services due to geographic barriers was most frequently selected. Multidose presentations with preservative or single-dose presentations were most frequently selected as desired vaccine attributes for facility-based settings while improved thermostability was most frequently selected for outreach and campaign settings. The second online survey was completed by 220 respondents in 54 countries. For the exemplar vaccines, vaccine ineffectiveness or wastage due to heat or freeze exposure and missed opportunities due to multidose vial presentations were identified as the greatest vaccine-specific challenges. In-depth interviews with 84 respondents in six countries ranked microarray patches, dual-chamber delivery devices, and heat-stable/controlled temperature chain qualified liquid vaccines as the three innovations that could have the greatest impact in helping address current immunization program challenges. These findings informed the VIPS prioritization and provided broader application to designing immunization interventions to better meet country needs.

1 December 2021 in Vaccine
Verified
Journal Article
Closed access
DKDebra Kristensen
Debra Kristensen
BGBirgitte K Giersing
Birgitte K Giersing
JHJulian Hickling
Julian Hickling
FKFatima Kazi
Fatima Kazi
TSTiziana Scarna
Tiziana Scarna
MMMarion Menozzi-Arnaud
Marion Menozzi-Arnaud

27 January 2023 in Expert Opinion on Drug Delivery
Verified
Journal Article
Open access
TSTiziana Scarnà
Tiziana Scarnà
MMMarion Menozzi-Arnaud
Marion Menozzi-Arnaud
MFMartin Friede
Martin Friede
KDKerry DeMarco
Kerry DeMarco
GPGeorge Plopper
George Plopper
BGBirgitte Giersing
Birgitte Giersing
: There is a need for investment in manufacturing for vaccine microarray patches (vMAPs) to accelerate vMAP development and access. vMAPs could transform vaccines deployment and reach to everyone, ...

19 September 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
MKMelissa Ko
Melissa Ko
CFCollrane Frivold
Collrane Frivold
MMMercy Mvundura
Mercy Mvundura
ASAdam Soble
Adam Soble
CGChristopher Gregory
Christopher Gregory
JAJean-Pierre Amorij
Jean-Pierre Amorij
Measles and rubella micro-array patches (MR-MAPs) are a promising innovation to address limitations of the current needle and syringe (N&S) presentation due to their single-dose presentation, ease of use, and improved thermostability. To direct and accelerate further research and interventions, an initial full value vaccine assessment (iFVVA) was initiated prior to MR-MAPs entering phase I trials to quantify their value and identify key data gaps and challenges. The iFVVA utilized a mixed-methods approach with rapid assessment of literature, stakeholder interviews and surveys, and quantitative data analyses to (i) assess global need for improved MR vaccines and how MR-MAPs could address MR problem statements; (ii) estimate costs and benefits of MR-MAPs; (iii) identify the best pathway from development to delivery; and (iv) identify outstanding areas of need where stakeholder intervention can be helpful. These analyses found that if MR-MAPs are broadly deployed, they can potentially reach an additional 80 million children compared to the N&S presentation between 2030–2040. MR-MAPs can avert up to 37 million measles cases, 400,000 measles deaths, and 26 million disability-adjusted life years (DALYs). MR-MAPs with the most optimal product characteristics of low price, controlled temperature chain (CTC) properties, and small cold chain volumes were shown to be cost saving for routine immunization (RI) in low- and middle-income countries (LMICs) compared to N&S. Uncertainties about price and future vaccine coverage impact the potential cost-effectiveness of introducing MR-MAPs in LMICs, indicating that it could be cost-effective in 16–81% of LMICs. Furthermore, this iFVVA highlighted the importance of upfront donor investment in manufacturing set-up and clinical studies and the critical influence of an appropriate price to ensure country and manufacturer financial sustainability. To ensure that MR-MAPs achieve the greatest public health benefit, MAP developers, vaccine manufacturers, donors, financiers, and policy- and decision-makers will need close collaboration and open communications.


24 March 2025 in Vaccine
Verified
Journal Article
Open access
CFCollrane Frivold
Collrane Frivold
BGBirgitte K Giersing
Birgitte K Giersing
JAJean-Pierre Amorij
Jean-Pierre Amorij
MMMercy Mvundura
Mercy Mvundura
MHMateusz Hasso-Agopsowicz
Mateusz Hasso-Agopsowicz
TSTiziana Scarna
Tiziana Scarna
Microarray patches (MAPs) have the potential to increase equitable vaccine coverage in low- and middle-income countries (LMICs). However, MAP developers and vaccine manufacturers have identified a barrier to development of MAPs for global health applications: the need for guidance on which vaccine MAPs would be of value to LMIC immunization programs. To address this gap, the Vaccine Innovation Prioritisation Strategy (VIPS) Alliance conducted a prioritization process to identify high-priority vaccines that could be delivered via MAPs in LMICs. We first compiled a reference list of vaccine targets through desk research, then filtered these targets based on route of administration, market distribution, existing interest from a global/regional health organization, whether the vaccine would address a specific global health priority or stakeholder agenda, development status, and potential MAP use cases. To further down-select the list, we consulted an external advisory group and evaluated the potential regulatory pathway, programmatic impact, and financial sustainability to define two priority levels. From a reference list of 91 vaccine targets, we identified 21 with applicability to LMICs, which were further down-selected to a VIPS priority list of 11 vaccine targets grouped by priority level. Priority group 1 included vaccines against hepatitis B virus, measles-rubella/measles-mumps-rubella viruses, human papillomavirus, rabies virus, yellow fever, influenza virus (seasonal and pandemic), and SARS-CoV-2. Priority group 2 included vaccines against Group B streptococcus, Neisseria meningitidis A,C,W,Y,(X), Salmonella Typhi, and Streptococcus pneumoniae. These vaccine MAP priorities will inform the investment decisions of MAP developers, vaccine manufacturers, donors, and global health partners to better respond to country needs when designing their MAP portfolios. By providing a holistic assessment of the potential drivers for and key risks of developing specific vaccine MAPs, our findings have the potential to promote MAP development activities for vaccines that are priorities for LMICs.